14.8% invasive local recurrence at 5y after BCS alone in TOP-1. Age 70+, small low-grade ER+ tumors, no RT or ET. Most recurrences were salvaged, but that is still more treatment. I'd be cautious about routinely omitting both. #ESMO26 #radonc https://t.co/QD1spCSEAb